Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FibroGen, Inc stock logo
FGEN
FibroGen
$9.77
+8.3%		$9.21
$4.85
▼
$12.60
$39.57M0.7740,794 shs31,125 shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$12.47
-0.6%		$11.06
$9.77
▼
$18.30
$2.19B0.2345,011 shs16,918 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$4.76
+2.5%		$4.76
$0.81
▼
$6.79
$388.29M1.451.61 million shs1.51 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%0.00%0.00%0.00%+16.73%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-0.64%+7.58%+12.65%-1.58%-19.44%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%0.00%0.00%0.00%+22.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FibroGen, Inc stock logo
FGEN
FibroGen
$9.77
+8.3%		$9.21
$4.85
▼
$12.60
$39.57M0.7740,794 shs31,125 shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$12.47
-0.6%		$11.06
$9.77
▼
$18.30
$2.19B0.2345,011 shs16,918 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$4.76
+2.5%		$4.76
$0.81
▼
$6.79
$388.29M1.451.61 million shs1.51 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%0.00%0.00%0.00%+16.73%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-0.64%+7.58%+12.65%-1.58%-19.44%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%0.00%0.00%0.00%+22.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FibroGen, Inc stock logo
FGEN
FibroGen
2.00
Hold$43.00340.12% Upside
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.17
Hold$14.8719.22% Upside
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.83
Moderate Buy$7.6761.23% Upside

Current Analyst Ratings Breakdown

Latest HCM, IMAB, and FGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D)
7/23/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$16.00 ➝ $14.00
7/17/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
7/7/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$20.00 ➝ $17.00
6/29/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
5/28/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$13.60
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FibroGen, Inc stock logo
FGEN
FibroGen
$29.62M1.34N/AN/A($50.89) per share-0.19
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$548.51M3.97$2.68 per share4.66$7.31 per share1.71
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/A$2.47 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FibroGen, Inc stock logo
FGEN
FibroGen
-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$456.91MN/AN/A56.68N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23M-$0.36N/AN/AN/AN/A-19.65%-18.58%N/A

Latest HCM, IMAB, and FGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026H1 2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$0.1450$0.05-$0.0950$0.05$304.16 million$139.14 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
FibroGen, Inc stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FibroGen, Inc stock logo
FGEN
FibroGen
N/A
3.71
3.60
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.06
5.64
5.50
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.82
22.82

Institutional Ownership

CompanyInstitutional Ownership
FibroGen, Inc stock logo
FGEN
FibroGen
72.71%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%

Insider Ownership

CompanyInsider Ownership
FibroGen, Inc stock logo
FGEN
FibroGen
3.07%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
FibroGen, Inc stock logo
FGEN
FibroGen
5704.05 million3.92 millionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,796174.47 million168.19 millionNot Optionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable

Recent News About These Companies

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a ...
October 29, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/i-mab-nasdaq-imab-transitions-to-novabridge-biosciences-nasdaq-nbp-with-trading-effective-october-30-2025-new-brand-and-logo-to-reflect-strategic-transformation-to-a-global-biotech-platform-1035447090
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
October 29, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/29/3176512/0/en/i-mab-nasdaq-imab-transitions-to-novabridge-biosciences-nasdaq-nbp-with-trading-effective-october-30-2025-new-brand-and-logo-to-reflect-strategic-transformation-to-a-global-biotech.html
I-Mab - Depositary Receipt (IMAB) Price Target Increased by 19.05% to 8.50
October 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/i-mab-depositary-receipt-imab-price-target-increased-by-19-05-to-8-50/ar-AA1PoMEr
BTIG Reiterates I-Mab - Depositary Receipt (IMAB) Buy Recommendation
October 24, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/btig-reiterates-i-mab-depositary-receipt-imab-buy-recommendation/ar-AA1P8sZs
I-MAB Reports Positive Phase I Results for Givastomig in Gastroesophageal Cancer
October 24, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/i-mab-reports-positive-phase-i-results-for-givastomig-in-gastroesophageal-cancer/ar-AA1P4EFA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
October 23, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-i-mab---imab-302591245.html
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
October 22, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/22/3171382/0/en/i-mab-to-present-positive-updated-givastomig-monotherapy-data-at-2025-aacr-nci-eortc-molecular-targets-and-cancer-therapeutics-conference-on-october-23-2025.html
I-Mab to rebrand as NovaBridge and target Hong Kong dual listing
October 17, 2025  |  thepharmaletter.comT
I-Mab tumbles after announcing new business model
October 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/i-mab-tumbles-after-announcing-new-business-model/ar-AA1OFTNG
I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript
October 17, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4830898-i-mab-imab-discusses-business-transformation-strategy-and-plans-for-accelerated-growth
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
October 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/16/3168300/0/en/i-mab-announces-intention-to-undertake-strategic-transformation-to-global-biotech-platform-to-pursue-hong-kong-ipo-and-rebrand-as-novabridge-biosciences.html
I-Mab Biopharma Stock: Caution Warranted After Huge Surge
October 14, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4829934-i-mab-biopharma-stock-caution-warranted-after-huge-surge
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/14/3166006/0/en/i-mab-to-present-short-talk-on-updated-givastomig-monotherapy-data-at-the-2025-aacr-nci-eortc-molecular-targets-and-cancer-therapeutics-conference.html
I-Mab's (NASDAQ:IMAB) market cap surged US$52m last week, individual investors who have a lot riding on the company were rewarded
October 11, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/mabs-nasdaq-imab-market-cap-121707049.html
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know
October 10, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2766496/i-mab-sponsored-adr-imab-is-up-24-14-in-one-week-what-you-should-know?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_10-2766496
What Makes IMab (IMAB) a New Buy Stock
October 6, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2762935/what-makes-imab-imab-a-new-buy-stock?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2762935
Leerink Partners Initiates Coverage of I-Mab - Depositary Receipt (IMAB) with Outperform Recommendation
October 4, 2025  |  msn.comhttps://www.msn.com/en-us/money/economy/leerink-partners-initiates-coverage-of-i-mab-depositary-receipt-imab-with-outperform-recommendation/ar-AA1NOQQl
I-Mab initiated with an Outperform at Leerink
October 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/i-mab-initiated-with-an-outperform-at-leerink/ar-AA1NNQGz
I-Mab to Vote on Name Change to NovaBridge Biosciences
September 25, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/i-mab-to-vote-on-name-change-to-novabridge-biosciences/ar-AA1NhWFJ
I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer
September 23, 2025  |  msn.comhttps://www.msn.com/en-us/health/medical/i-mab-imab-shows-83-response-rate-for-givastomig-in-metastatic-gastric-cancer/ar-AA1Nau7r

New MarketBeat Followers Over Time

Media Sentiment Over Time

FibroGen stock logo

FibroGen NASDAQ:FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$12.47 -0.08 (-0.64%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$12.48 +0.01 (+0.12%)
As of 08/11/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

I-Mab stock logo

I-Mab NASDAQ:IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas